IP Library Granted Patent US 7,592,431
Granted Patent B2
US 7,592,431 · App. 11/601,446 · Granted Sep 22, 2009

Biodegradable T-cell Activation device

Assignee: Immunovative Therapies, Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,592,431
App. No.
11/601,446
Granted
Sep 22, 2009
Kind
B2
Abstract

A biodegradable device for activating T-cells includes a biodegradable support and a binder attached to the biodegradable support, the binder having reactivity to one or more agents capable of binding to a T-cell surface antigen.

Claims (12)

1. A biodegradable device for activating T-cells, the device comprising:

a biodegradable support; and

a first material attached to the biodegradable support, wherein the first material is an antibody capable of cross-linking more than one second material, the second material capable of binding to a T-cell surface antigen.

2. The biodegradable device of claim 1 wherein the biodegradable support comprises collagen, gelatin, albumen or polysaccharides.

3. The biodegradable device of claim 1 wherein the biodegradable support comprises aliphatic polyesters.

4. The biodegradable device of claim 1 wherein the second materials have reactivity to T-cell surface antigens.

5. The biodegradable device of claim 1 wherein the first material comprises polyclonal or monoclonal antibodies, or fragments thereof.

6. The biodegradable device of claim 1 wherein the first material is attached to the biodegradable support with glutaraldehyde.

7. The biodegradable device of claim 6 and further comprising diaminoheptane spacer groups.

8. The biodegradable device of claim 1 wherein the second materials include mitogenic proteins, monoclonal antibodies, fusion proteins and agents capable of binding to chemokine receptors.

9. The biodegradable device of claim 8 wherein the mitogenic proteins include anti-CD3 and anti-CD2 monoclonal antibodies.

10. The biodegradable device of claim 9 and further including co-stimulatory proteins that are specific for one or more T-cell surface molecules.

Assignments (5)
CORRECTIVE ASSIGNMENT TO CORRECT THE CORRECT THE ADDRESS OS THE ASSIGNEE PREVIOUSLY RECORDED AT REEL: 050489 FRAME: 0245. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jan 28, 2020
From: HAR-NOY, MICHAEL
To: MIRROR BIOLOGICS, INC.
Reel/Frame 052915/0513 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR'S NAME FROM IMMUNOVATIVE THERAPIES, LTD. TO MICHAEL HAR-NOY ON THE ORIGINAL COVER SHEET PREVIOUSLY RECORDED ON REEL 050489 FRAME 0245. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Oct 2, 2019
From: HAR-NOY, MICHAEL
To: MIRROR BIOLOGICS, INC.
Reel/Frame 050610/0633 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 25, 2019
From: IMMUNOVATIVE THERAPIES, LTD.
To: MIRROR BIOLOGICS, INC.
Reel/Frame 050489/0245 →
RESCISSION Recorded Sep 12, 2019
From: HAR-NOY, MICHAEL
To: HAR-NOY, MICHAEL
Reel/Frame 050467/0081 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 29, 2006
From: HAR-NOY, MICHAEL
To: IMMUNOVATIVE THERAPIES, LTD.
Reel/Frame 018751/0685 →
Continuity (3)
Continuation In Part 1106613300 · Feb 24, 2005
Provisional Application 6054796600 · Feb 26, 2004
Related Publication 20070086996A1 · Apr 19, 2007